CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03082534
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:32.530273+00:00
Published At: 2026-01-28T00:00:00+00:00
Record Updated At: 2026-01-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HNSCC", "Lip SCC", "Oral Cavity Cancer", "Oropharynx Cancer", "Larynx Cancer", "Hypopharynx Cancer", "Nasopharynx Cancer", "Sinonasal Carcinoma", "Cutaneous Squamous Cell Carcinoma", "Head and Neck Neoplasms", "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-28"
protocolSection.identificationModule.nctId: "NCT03082534"
protocolSection.identificationModule.officialTitle: "An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.